| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.lactoseindia.com | |
| Market Cap | 97.56 Cr. | |
| Enterprise Value(EV) | 131.85 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 1.95 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 39.82 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 28.47 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 31.21 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 2.48 | Calculated using Price: 77.50 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 1.26 Cr. | 12,589,000 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Lactose (India), a Toshniwal Group company, was incorporated in 1991, under the Companies Act, 1956. Its plant in Vadodara, Gujarat was commissioned by Alfa Laval, Pune (which is a subsidary of Alfa Laval of Sweden) and was also given a ‘thumbs up’ by reputed dairy experts from the Netherlands in October 1991. Subsequently Alfa Laval, reputed dairy experts from Sweden and a joint commission from the Netherlands studied the plant and its working and confidently acknowledged the plant for its quality standards as well. For ten years now, Lactose (India) Limited has stood for perfection, quality, constant innovation and complete dedication to their clients. With up to date technology, the company is one of India's leading producers of Edible and Pharmaceutical grade Lactose. Apart from this, the company also manufactures Dairy Whitener, Dairy Calcium, Whey Powder, Casein, Caseinate, Butter and Ghee. The company still boasts of being the first company to manufacture Lactose in the Asian subcontinent. The company has since grown to be a leading player in the Lactose market and continues to supply consistent quality Lactose to several global giants in the pharmaceutical world. It commands a 40% overall market share and this makes the company the leading Lactose supplier in the country. With its unparalled infrastructure of requisite equipment and dedicated work force, Lactose (India) has a state of the art manufacturing facility for contract manufacturing of pharmaceutical products.The latest in its diverse interests is the manufacturing of pharmaceutical formulations for Aventis Pharma (earlier-Hoechst Marion Roussel), for the purpose of domestic use and export to Russia. The state of art manufacturing facilities for the manufacture of pharmacuetical formulations is in compliance with all international standards.The plant is approved under WHO-cGMP guidelines and also holds TUV certificate as an ISO 9001 : 2000 company.The manufacturing facilities include wet granulation,Fluid bed drying, compaction, blending and coating facilities with the latest technology equipments.The manufacturing facilities is well supported by its total in-house Quality Control set-up with latest Testing equipments and an upto date Microbiology Testing Laboratory. The facility is supported by an equally competent and FDA approved Manufacturing professionals. Besides providing lactose for pharmaceutical giants, food,confectionary and dairy companies in India, the company's product also leaves Indian shores for the African continent, South East Asia, and some of its other neighbouring countries. After achieving its ambitious goal of being the most successful and leading Lactose manufacturer and supplier in the country, the company is now venturing aggressively into exports of pharmaceuticals and related products. Product range of the company includes:
Awards & Achievements:
|
||
Company Profile
Lactose (India), a Toshniwal Group company, was incorporated in 1991, under the Companies Act, 1956. Its plant in Vadodara, Gujarat was commissioned by Alfa Laval, Pune (which is a subsidary of Alfa Laval of Sweden) and was also given a ‘thumbs up’ by reputed dairy experts from the Netherlands in October 1991. Subsequently Alfa Laval, reputed dairy experts from Sweden and a joint commission from the Netherlands studied the plant and its working and confidently acknowledged the plant for its quality standards as well.
For ten years now, Lactose (India) Limited has stood for perfection, quality, constant innovation and complete dedication to their clients. With up to date technology, the company is one of India's leading producers of Edible and Pharmaceutical grade Lactose. Apart from this, the company also manufactures Dairy Whitener, Dairy Calcium, Whey Powder, Casein, Caseinate, Butter and Ghee.
The company still boasts of being the first company to manufacture Lactose in the Asian subcontinent. The company has since grown to be a leading player in the Lactose market and continues to supply consistent quality Lactose to several global giants in the pharmaceutical world. It commands a 40% overall market share and this makes the company the leading Lactose supplier in the country.
With its unparalled infrastructure of requisite equipment and dedicated work force, Lactose (India) has a state of the art manufacturing facility for contract manufacturing of pharmaceutical products.The latest in its diverse interests is the manufacturing of pharmaceutical formulations for Aventis Pharma (earlier-Hoechst Marion Roussel), for the purpose of domestic use and export to Russia.
The state of art manufacturing facilities for the manufacture of pharmacuetical formulations is in compliance with all international standards.The plant is approved under WHO-cGMP guidelines and also holds TUV certificate as an ISO 9001 : 2000 company.The manufacturing facilities include wet granulation,Fluid bed drying, compaction, blending and coating facilities with the latest technology equipments.The manufacturing facilities is well supported by its total in-house Quality Control set-up with latest Testing equipments and an upto date Microbiology Testing Laboratory. The facility is supported by an equally competent and FDA approved Manufacturing professionals.
Besides providing lactose for pharmaceutical giants, food,confectionary and dairy companies in India, the company's product also leaves Indian shores for the African continent, South East Asia, and some of its other neighbouring countries.
After achieving its ambitious goal of being the most successful and leading Lactose manufacturer and supplier in the country, the company is now venturing aggressively into exports of pharmaceuticals and related products.
Product range of the company includes:
Awards & Achievements:
| 1 Day |
|
+4.94% |
| 1 Week |
|
+17.25% |
| 1 Month |
|
+11.03% |
| 3 Month |
|
+43.65% |
| 6 Month |
|
+100.52% |
| 1 Year |
|
+168.63% |
| 2 Year |
|
+323.50% |
| 5 Year |
|
-41.24% |
| 10 Year |
|
+715.79% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 7.14 | 0.18 | 3.25 | 15.69 | 11.95 | -4.59 | 2.20 | 0.21 | -7.21 | |
| Return on Capital Employed (%) | 9.25 | 3.69 | 7.55 | 14.75 | 14.78 | 4.08 | 9.13 | 7.84 | 2.81 | |
| Return on Assets (%) | 2.35 | 0.05 | 0.71 | 3.44 | 3.30 | -1.59 | 0.88 | 0.09 | -2.88 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 15 | 15 | 16 | 20 | 27 | 32 | 34 | 34 | 35 | 39 | |
| Non Curr. Liab. | 15 | 30 | 44 | 37 | 31 | 38 | 35 | 38 | 42 | 36 | |
| Curr. Liab. | 17 | 16 | 20 | 26 | 27 | 13 | 12 | 11 | 12 | 15 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 47 | 60 | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | |
| Non Curr. Assets | 27 | 47 | 67 | 66 | 68 | 66 | 64 | 64 | 69 | 67 | |
| Curr. Assets | 20 | 13 | 13 | 17 | 17 | 17 | 18 | 20 | 20 | 23 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 47 | 60 | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 47 | 22 | 24 | 34 | 36 | 31 | 41 | 40 | 35 | 46 | |
| Other Income | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | |
| Total Income | 47 | 23 | 24 | 36 | 37 | 32 | 41 | 40 | 35 | 47 | |
| Total Expenditure | -44 | -21 | -19 | -24 | -24 | -25 | -31 | -31 | -29 | -34 | |
| PBIDT | 4 | 2 | 5 | 12 | 12 | 6 | 10 | 10 | 7 | 13 | |
| Interest | -1 | -1 | -3 | -4 | -4 | -5 | -5 | -6 | -5 | -5 | |
| Depreciation | -2 | -2 | -2 | -3 | -3 | -4 | -4 | -4 | -4 | -5 | |
| Taxation | 0 | 0 | 0 | -1 | -2 | 1 | 0 | 0 | 1 | -1 | |
| Exceptional Items | 2 | ||||||||||
| PAT | 1 | 0 | 1 | 3 | 3 | -1 | 1 | 0 | -2 | 2 | |
| Adjusted EPS | 1 | 0 | 1 | 3 | 3 | -1 | 1 | 0 | -2 | 2 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | -3 | 14 | 7 | 13 | 1 | 8 | 0 | 5 | 7 | 2 | |
| Cash Fr. Inv. | -3 | -14 | -21 | -23 | 3 | -5 | -2 | -2 | -3 | -6 | |
| Cash Fr. Finan. | 6 | 1 | 13 | 10 | -5 | -3 | 4 | -5 | -4 | 5 | |
| Net Change | 0 | 1 | -1 | -1 | 0 | 0 | 3 | -2 | 1 | 1 | |
| Cash & Cash Eqvt | 0 | 1 | 1 | 0 | 0 | 0 | 3 | 1 | 2 | 2 |
|
Thu, 19 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication In terms of Regulation 30 and Regulation 47(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR) please find attached newspaper cuttings of the advertisement in relation to the financial results for the fourth quarter and Financial Year ended on 31st March 2022 as specified in Regulation 33 of LODR published in Business Standard (English) and Vadodara Samachar (Gujarati) on 19th May 2022. |
|
Tue, 17 May 2022
Board Meeting Outcome for Board Meeting Held On 17Th May 2022 In compliance with Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform that the Board of Directors of the Company at their meeting held on 17th May 2022 has inter alia considered and approved the followings items of agenda: 1. Audited Financial Results along with Auditors Report for the Fourth quarter and Financial year ended 31st March 2022; 2. Audited Financial Statements of the company for the Financial year ended 31st March 2022; 3. Re-appointment of Internal Auditor for FY 2022-23; 4. Noting of resignation of M/s. Jajodia & Associates Secretarial Auditor of the company; 5. Appointment of Ms. Bhumika Sidhpura as Secretarial Auditor of the company for the FY 2021-2022 & 2022-2023; |
|
Tue, 17 May 2022
Intimation Regarding Resignation Of Secretarial Auditor Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations"). Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that M/s. Jajodia & Associates Practicing Company Secretaries has resigned as the Secretarial Auditor of the Company due to pre occupation for Financial year 2021-2022 vide resignation letter 16th May 2022. |
| Thu, 19 May 2022 |
High Delivery Percentage
|
Higher Delivery Quantity
|
Higher Delivery Quantity and Percentage
|
Close Crossing Last Month Close From Below
|
Opening at High
|
Equities
M.F.
Sectors